Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Takara, Kohji ^a   Yamamoto, Kazuhiro ^b   Matsubara, Mika ^b   Minegaki, Tetsuya ^b   Takahashi, Minoru ^a   Yokoyama, Teruyoshi ^a   Okumura, Katsuhiko ^a  

^a HIMEJI DOKKYO UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DIHYDROERGOTAMINE; DOXAZOSIN; ERGOTAMINE; HOE 33342; MESSENGER RNA; MITOXANTRONE; NAFTOPIDIL; PRAZOSIN; TERAZOSIN; TOLAZOLINE; URAPIDIL; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; FLOW CYTOMETRY; HELA CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CHEMISTRY; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; NEOPLASM; REAL TIME POLYMERASE CHAIN REACTION; TRANSPORT AT THE CELLULAR LEVEL; WESTERN BLOTTING;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HELA CELLS; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ADRENERGIC, ALPHA-1; RNA, MESSENGER;

EID: 84857098182     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030697     Document Type: Article

References (28)

1. Gottesman MM, Fojo T, Bates SE, (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
2. Simon SM, Schindler M, (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91: 3497-3504.
3. Fletcher JI, Haber M, Henderson MJ, Norris MD, (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10: 147-156.
4. Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y, (2009) Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev 61: 26-33.
5. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, et al. (2004) Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10: 1691-1697.
6. Liao CH, Guh JH, Chueh SC, Yu HJ, (2011) Anti-angiogenic effects and mechanism of prazosin. Prostate 71: 976-984.
7. Pool JL, Kirby RS, (2001) Clinical significance of α1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int Urol Nephrol 33: 407-412.
8. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, et al. (2007) Effect of α1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178: 2176-2180.
9. Pan SL, Guh JH, Huang YW, Chern JW, Chou JY, et al. (2003) Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol 169: 724-729.
10. Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, et al. (2009) The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos 37: 946-955.
11. Xiao Y, Davidson R, Smith A, Pereira D, Zhao S, et al. (2006) A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm 3: 45-54.
12. Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, et al. (2009) Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett 278: 88-96.
13. Benning CM, Kyprianou N, (2002) Quinazoline-derived α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an α1-adrenoceptor-independent action. Cancer Res 62: 597-602.
14. Tahmatzopoulos A, Rowland RG, Kyprianou N, (2004) The role of α-blockers in the management of prostate cancer. Expert Opin Pharmacother 5: 1279-1285.
15. Partin JV, Anglin IE, Kyprianou N, (2003) Quinazoline-based α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signaling and IκBα induction. Br J Cancer 88: 1615-1621.
16. Siddiqui EJ, Shabbir M, Thompson CS, Mumtaz FH, Mikhailidis DP, (2005) Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved? Anticancer Res 25: 4281-4286.
17. Kojima Y, Sasaki S, Oda N, Koshimizu TA, Hayashi Y, et al. (2009) Prostate growth inhibition by subtype-selective α(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia. Prostate 69: 1521-1528.
18. Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, et al. (2008) Naftopidil, a selective α-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer 122: 444-451.
19. Hori Y, Ishii K, Kanda H, Iwamoto Y, Nishikawa K, et al. (2011) Naftopidil, a selective α1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila) 4: 87-96.
20. Mulac D, Humpf HU, (2011) Cytotoxicity and accumulation of ergot alkaloids in human primary cells. Toxicology 282: 112-121.
21. Koceva-Chyła A, Jedrzejczak M, Skierski J, Kania K, Jóźwiak Z, (2005) Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis 10: 1497-1514.
22. Cruise JL, Houck KA, Michalopoulos GK, (1985) Induction of DNA synthesis in cultured rat hepatocytes through stimulation of α1 adrenoreceptor by norepinephrine. Science 227: 749-751.
23. Hu ZW, Shi XY, Lin RZ, Hoffman BB, (1996) α1 adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells. Role in mitogenesis. J Biol Chem 271: 8977-8982.
24. Kim RK, Wandel C, Leake B, Cvetkovic M, Fromm MF, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16: 408-414.
25. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, et al. (2009) Effects of α-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res 17: 527-533.
26. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, et al. (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011-2021.
27. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, et al. (2002) Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25: 771-778.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.